In this presentation, the presenters will discuss the design, outcomes, and clinical implications of the phase II RADIOSA trial, which evaluated stereotactic body radiotherapy (SBRT) alone versus SBRT combined with short-course androgen deprivation therapy (ADT) in patients with hormone-sensitive oligo-recurrent prostate cancer. The session will explore patient selection criteria, treatment strategies, progression-free survival outcomes, and translational biomarker analyses, highlighting the potential role of treatment intensification in a biologically heterogeneous setting.
Learning Objectives:
1- Understand the clinical rationale and trial design of the RADIOSA study, including inclusion criteria and endpoints relevant to oligorecurrent prostate cancer.
2 – Evaluate the efficacy and toxicity outcomes of SBRT with or without ADT and their implications for routine clinical practice.
3 – Discuss ongoing translational research and future directions for biomarker integration and treatment personalization in oligometastatic prostate cancer.
This webinar is pending approval by CAMPEP for 1 MPCEC hour and ASRT for 1 category A credit.
Presenters: Barbara Alicja Jereczek-Fossa, MD, PhD
Barbara Alicja Jereczek-Fossa, MD, PhD, is Full Professor of Radiation Oncology at UNIMI and Chair of the Radiation Oncology Department, including the Proton Center, at European Institute of Oncology, Milan, Italy. She is President Elect of ESTRO and serves on key scientific boards, including APCCC, ESO and EuropaUomo. She is PI of the AIRC-funded studies on prostate cancer, including the RADIOSA randomised phase II trial on prostate cancer oligorecurrences, the GIVE-ME-FIVE phase II study on prostate SBRT with intraprostatic boost, the GREEN Radiotherapy initiative on sustainable hypofractionation (Multilayered Urban Sustainability Action MUSA project), and the STRA-MI-VT cardiac radioablation phase I/II trial. Her research explores SBRT and hypofractionation, AI and radiomics (e.g., ESTRO-AAPM AI Guidelines, DECIDE project), proton therapy (POWER Registry) and drug radiation combinations. Author of nearly 500 publications (almost 200 regarding prostate cancer), she holds an H-index of 58 (13.100 citations) and ranks among the Top Italian and Stanford University’s World’s Top 2% Scientists.
Giulia Marvaso, M.D.
Dr. Giulia Marvaso is a radiation oncologist and Assistant Professor at the University of Milan, affiliated with the European Institute of Oncology (IEO), Milan. Her clinical expertise centers on genitourinary malignancies, particularly prostate and kidney cancers. She plays an integral role in multidisciplinary care, with a focus on high-precision techniques such as stereotactic body radiotherapy (SBRT) and image-guided radiotherapy.
Dr. Marvaso’s research encompasses translational and clinical investigations into oligometastatic disease, radiotherapy-drug combinations, and biomarkers for treatment response. She is an active contributor to international cooperative trials and consensus guidelines. Her most recent publication in The Lancet Oncology (2024) presents an ESTRO-EAU Delphi consensus on SABR for oligometastatic and oligoprogressive renal cell carcinoma. She also co-led the RADIOSA phase II trial on SBRT with or without ADT in oligorecurrent prostate cancer, highlighting her commitment to advancing evidence-based, personalized oncology (The Lancet Oncology 2025).
Giovanni Carlo Mazzola, M.D.
Dr. Giovanni Carlo Mazzola is a Radiation Oncologist at the European Institute of Oncology (IEO) in Milan. Since 2022, he has served as a full-time Medical Specialist in the Division of Radiation Oncology.
Dr. Mazzola’s clinical expertise centers on uro-oncological malignancies, including prostate, bladder and kidney cancers, with particular expertise in stereotactic body radiotherapy (SBRT), radiosurgery, and proton therapy. He also actively participates in multidisciplinary tumor boards.
An accomplished researcher, Dr. Mazzola has authored articles appearing in peer-reviewed international journals, with notable contributions to the fields of SBRT, oligometastatic disease management, and proton therapy.
In addition to his clinical and research roles, Dr. Mazzola collaborates with the University of Milan where he delivers lectures and assesses medical students in Diagnostic Imaging and Radiotherapy, contributing to the next generation of oncologists.
